Sciwind Biosciences

About Sciwind Biosciences

Based in Hangzhou, China, Sciwind Biosciences is a clinical-stage biopharmaceutical company established in 2017. The company was founded by Dr. Hai Pan, who currently serves as Chairman and CEO. Dr. Pan brings over two decades of R&D executive and entrepreneurial experience in the pharmaceutical industry, having previously held leadership positions at Amgen and Kawin Biotech and successfully advanced more than 20 drug candidates into clinical development. His expertise in metabolic and infectious diseases shapes the company's strategic focus.

Sciwind is dedicated to developing therapies for metabolic diseases, specifically targeting type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). The company operates on a business model centered around the discovery, development, and commercialization of its drug candidates. Its revenue generation strategy involves forming licensing and collaboration agreements with other biopharmaceutical companies. A notable example is the global licensing deal with Verdiva Bio for a portfolio of metabolic disease therapies, which included an upfront consideration of approximately $70 million and potential milestone payments exceeding $2.4 billion, plus royalties. Sciwind has successfully raised significant capital, including a Series C funding round of $70 million in October 2021, co-led by IDG Capital, Loyal Valley Capital, and LYFE Capital, bringing its total raised funds to over $136 million.

The company's product pipeline features several drug candidates built upon its proprietary technologies, such as oral peptide and inhaled protein therapeutic delivery platforms. Key programs include Ecnoglutide (XW003), a long-acting GLP-1 peptide analog for once-weekly injection, which has reached Phase 3 clinical trials for obesity and type 2 diabetes. Sciwind is also advancing oral formulations, such as XW004, a daily pill version of Ecnoglutide, and XW014, a small molecule GLP-1 receptor agonist. These oral candidates offer greater patient convenience and the potential for combination therapies. The pipeline further includes amylin analogs like XW015 and XW016, and a GIP peptide analog, XW017, designed for combination treatments to enhance efficacy.